We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-4.41%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.21B
AUM Growth
-$804M
Cap. Flow
-$184M
Cap. Flow %
-2.96%
Top 10 Hldgs %
40.63%
Holding
166
New
10
Increased
38
Reduced
80
Closed
12

Top Buys

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$32.4M
2
UNH icon
UnitedHealth
UNH
+$23.7M
3
CI icon
Cigna
CI
+$21.4M
4
HUM icon
Humana
HUM
+$20.1M
5
APLS
Apellis Pharmaceuticals
APLS
+$12.1M

Top Sells

Rank Stock Value
1
INSP icon
Inspire Medical Systems
INSP
+$72.3M
2
MDT icon
Medtronic
MDT
+$64.4M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$33M
4
CRL icon
Charles River Laboratories
CRL
+$17.5M
5
TMO icon
Thermo Fisher Scientific
TMO
+$15.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.13%
2 Industrials 0.77%
3 Energy 0.04%
4 Communication Services 0.01%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARGX icon
1
argenx
ARGX
$53.8B
$448M 7.22%
911,530
-11,754
-1% -$5.75M
IONS icon
2
Ionis Pharmaceuticals
IONS
$8.99B
$419M 6.75%
9,233,700
-146,600
-2% -$6.05M
VRTX icon
3
Vertex Pharmaceuticals
VRTX
$123B
$349M 5.62%
1,002,735
-94,431
-9% -$33M
NBIX icon
4
Neurocrine Biosciences
NBIX
$17.2B
$291M 4.68%
2,583,550
-29,250
-1% -$3.08M
ISRG icon
5
Intuitive Surgical
ISRG
$122B
$242M 3.9%
828,999
-13,225
-2% -$4.13M
ITCI
6
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$165M 2.66%
3,170,250
-31,550
-1% -$1.84M
ALNY icon
7
Alnylam Pharmaceuticals
ALNY
$35.7B
$158M 2.55%
894,345
-5,305
-0.6% -$1.01M
MRNA icon
8
Moderna
MRNA
$24.5B
$154M 2.49%
1,495,325
-29,734
-2% -$3.32M
ABT icon
9
Abbott
ABT
$175B
$151M 2.44%
1,560,968
-85,533
-5% -$8.98M
INCY icon
10
Incyte
INCY
$23.4B
$144M 2.32%
2,491,450
-149,315
-6% -$9.41M
BSX icon
11
Boston Scientific
BSX
$65.4B
$140M 2.25%
2,646,295
-15,157
-0.6% -$795K
RVMD icon
12
Revolution Medicines
RVMD
$39.6B
$131M 2.11%
4,721,500
-24,500
-0.5% -$727K
UNH icon
13
UnitedHealth
UNH
$387B
$130M 2.1%
258,205
+48,078
+23% +$23.7M
SYK icon
14
Stryker
SYK
$123B
$130M 2.09%
475,613
-1,333
-0.3% -$382K
AXNX
15
DELISTED
Axonics, Inc. Common Stock
AXNX
$126M 2.04%
2,252,851
+29,433
+1% +$1.66M
EVH icon
16
Evolent Health
EVH
$654M
$100M 1.61%
3,677,115
+228,793
+7% +$6.36M
AGIO icon
17
Agios Pharmaceuticals
AGIO
$2.36B
$99.3M 1.6%
4,013,500
– –
HUM icon
18
Humana
HUM
$48B
$82.7M 1.33%
170,046
+42,673
+34% +$20.1M
INSM icon
19
Insmed
INSM
$23.5B
$79.9M 1.29%
3,162,735
-138,176
-4% -$3.16M
BDX icon
20
Becton Dickinson
BDX
$43.6B
$78.7M 1.27%
304,230
-33,493
-10% -$9.05M
EXAS
21
DELISTED
Exact Sciences
EXAS
$76.4M 1.23%
1,119,819
+113,047
+11% +$9.59M
ELV icon
22
Elevance Health
ELV
$80.9B
$75.7M 1.22%
173,887
+71,434
+70% +$32.4M
OPCH icon
23
Option Care Health
OPCH
$3.41B
$73.9M 1.19%
2,284,293
-3,330
-0.1% -$112K
SAGE
24
DELISTED
Sage Therapeutics
SAGE
$72.3M 1.16%
3,513,351
+398,976
+13% +$11.5M
EW icon
25
Edwards Lifesciences
EW
$49.4B
$71M 1.14%
1,025,457
-12,635
-1% -$1.02M
1
2 3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2023 Portfolio in Review

As of Q3 2023, Bellevue Group held 166 positions worth $6.21B, down 11% from $7.01B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Bellevue Group's Q3 2023 filing shows 10 new, 38 increased, 80 reduced and 12 closed positions. Its largest new stake was Viatris: 176,848 shares worth $1.74M. The largest sale was Inspire Medical Systems, an estimated $72.3M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Industrials and Energy.

  • Bellevue Group's largest Q3 2023 buy was Viatris: 176,848 shares worth $1.74M.
  • Bellevue Group added most to Elevance Health in Q3 2023, an estimated $32.4M increase.
  • Bellevue Group's biggest Q3 2023 reduction was Inspire Medical Systems, cutting an estimated $72.3M.
  • Bellevue Group fully exited Baxter International in Q3 2023, selling an estimated $9.72M.
  • Bellevue Group's ten largest holdings make up 41% of its $6.21B portfolio in Q3 2023.
  • Bellevue Group opened 10 new positions and closed 12 in Q3 2023.
  • Bellevue Group's portfolio value fell 11% quarter-over-quarter to $6.21B.

Based on Bellevue Group's 13F filing for Q3 2023, filed 14 Nov 2023.